Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Preliminary Fiscal Q1 Revenues Down 27 Percent on COVID Sales Decline

NEW YORK – Hologic said on Sunday that its preliminary fiscal 2023 first quarter revenues are expected to decline 27 percent year over year on softer COVID-19-related test sales.

For the three months ending Dec. 31, the company anticipates revenues to shrink to $1.07 billion from $1.47 billion a year ago, but still above the analysts' average estimate of $966.4 million.

The projected totals would also beat the firm's Q1 revenue guidance of $940 million to $990 million announced Oct. 31.

The expected overall revenue decline is mostly related to waning COVID-19 testing revenue, although the Marlborough, Massachusetts-based firm gained back some of that ground through its other organic molecular diagnostics business. It expects overall diagnostic business revenues of $559.3 million for the quarter, down 41 percent from $950.4 million in the year-ago quarter. Its organic diagnostics business revenues excluding COVID-19 testing are expected to rise 12 percent, to $387.7 million from $345.5 million, and its organic molecular diagnostics business excluding COVID-19 testing are projected to rise 22 percent, to $260.9 million from $214.8 million.

First quarter Breast Health revenues are expected to be $334.2 million, down 7 percent year over year from $359.3 million, while Gynecologic Surgical revenues are expected to be $154.1 million, a 15 percent rise year over year from $134.3 million, and Skeletal Health revenues are expected to total $26.6 million, a 2 percent drop from $27.1 million a year ago.

“We delivered robust revenue performance in our fiscal first quarter of 2023, with our Diagnostics and Surgical businesses growing organically double-digits in constant currency, excluding COVID,” Hologic CEO Steve MacMillan said in a statement. “In addition, recovery in our Breast Health business is underway, with results ahead of our prior estimate for the quarter.”

The firm expects Q1 non-GAAP diluted earnings per share to be above its guidance of $.80 to $.90 announced Oct. 31.

In early trading on the Nasdaq, Hologic's shares were up 4 percent to $81.04 per share on the Nasdaq.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.